A combination therapy approach provides an attractive option in the management of ER-/AR+ breast cancer, since it exploits the synergy between AR and MEK inhibitors and at the same time minimizes their potential toxicities by requiring a lower dose of each agent in the combination setting. Here, MAP2K7 is linked to breast cancer.